

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/051,320
Filing Date	1/18/02
First Named Inventor	H. Michael Shepard
Art Unit	1617
Examiner Name	Criares, Theodore J.
Attorney Docket Number	NB 2019.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
12	1	AUPPERLE, K. et al., "Regulation of Synovocyte Proliferation, Apoptosis, and Invasion by the p53 Tumor Suppressor Gene, (April, 1998) <i>American Journal of Pathology</i> , Vol 152, No. 4	
	2	ZUONING, H et al., Dominant-Negative p53 Mutations in Rheumatoid Arthritis, (1999) <i>Arthritis & Rheumatism</i> 42: No. 6, June PP 1088-1092	
	3	International Search Report, International application No. PCT/US02/01361, dtd 16 Dec, 2002	
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		

Examiner's
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.